Research records indexed for Afamelanotide
This page carries 12 of the 105 records that the literature query returned for Afamelanotide, selected by citation count and preferring records that name the compound in their title. It is a selection, not a complete index, and the 93 records it does not carry are not represented here. Every row resolves to a real identifier and names the study model, so no finding reads as a human claim by default. The compound page is Afamelanotide.
Indexed records
| Record | Year | Study type | Model | n as stated | What it reported |
|---|---|---|---|---|---|
| Investigation of the stability profile of therapeutic α-MSH analogue: Insights from liquid chromatography-high resolution mass spectrometry analysis of afamelanotide pmid:41547183 | 2026 | Journal Article | other | Not stated | Indexed as journal article. study model from assigned MeSH headings do not state a study model. subject headings: Alpha-MSH; Chromatography, High Pressure Liquid; Drug Stability; Ultraviolet Rays; Oxidative Stress. |
| German Cohort Observational Study to Investigate the Short- and Long-Term Safety and Clinical Effectiveness of Afamelanotide 16 mg (SCENESSE) in Patients With Erythropoietic Protoporphyria (EPP) pmid:40082741 | 2025 | research-article, Multicenter Study | other | Not stated | Indexed as research-article, multicenter study. study model from MeSH "Humans" with no interventional publication type. subject headings: Protoporphyria, Erythropoietic; Alpha-MSH; Registries; Quality Of Life; Child, Preschool. |
| The effects of cholecalciferol and afamelanotide on vitamin D levels in erythropoietic protoporphyria: a multicentre cohort study pmid:38634774 | 2024 | Multicenter Study, Observational Study | other | Not stated | Indexed as multicenter study, observational study. study model from MeSH "Humans" with no interventional publication type. subject headings: Protoporphyria, Erythropoietic; Vitamin D Deficiency; Cholecalciferol; Alpha-MSH; Vitamin D. |
| Erythropoietic protoporphyria and afamelanotide: a patient's perspective pmid:37831089 | 2024 | Journal Article | other | Not stated | Indexed as journal article. study model from MeSH "Humans" with no interventional publication type. subject headings: Protoporphyria, Erythropoietic; Alpha-MSH. |
| Vitamin D status in patients with erythropoietic protoporphyria taking the systemic photoprotective agent afamelanotide pmid:38736212 | 2024 | Comment, Editorial | other | Not stated | Indexed as comment, editorial. study model from MeSH "Humans" with no interventional publication type. subject headings: Protoporphyria, Erythropoietic; Vitamin D Deficiency; Alpha-MSH; Vitamin D; Sunscreening Agents. |
| Erythropoietic protoporphyria in the Netherlands: Clinical features, psychosocial impact and the effect of afamelanotide pmid:36579412 | 2023 | Journal Article | other | Not stated | Indexed as journal article. study model from MeSH "Humans" with no interventional publication type. subject headings: Protoporphyria, Erythropoietic; Pain; Alpha-MSH; Longitudinal Studies; Prospective Studies. |
| Association of quality of life measures with afamelanotide treatment in patients with erythropoietic protoporphyria and x-linked protoporphyria: A retrospective cohort study pmid:36244556 | 2023 | Journal Article | other | Not stated | Indexed as journal article. study model from MeSH "Humans" with no interventional publication type. subject headings: Protoporphyria, Erythropoietic; Genetic Diseases, X-Linked; Alpha-MSH; 5-Aminolevulinate Synthetase; Retrospective Studies. |
| A feasibility and safety study of afamelanotide in acute stroke patients - an open label, proof of concept, phase iia clinical trial pmid:37496004 | 2023 | Clinical Trial, Phase II, research-article | human trial | Not stated | Indexed as clinical trial, phase ii, research-article. study model from MeSH "Humans" with publication type "clinical trial, phase ii". subject headings: Brain Ischemia; Alpha-MSH; Feasibility Studies; Aged, 80 And Over; Stroke. |
| Into the Light: Afamelanotide and the Treatment of Erythropoietic Protoporphyria in the United States pmid:37683058 | 2023 | Journal Article | other | Not stated | Indexed as journal article. study model from MeSH "Humans" with no interventional publication type. subject headings: Protoporphyria, Erythropoietic; Pain; Dermatitis, Phototoxic; Alpha-MSH. |
| Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria pmid:33507118 | 2021 | Review | other | Not stated | Indexed as review. study model from MeSH "Animals" with no rodent species heading. subject headings: Protoporphyria, Erythropoietic; Pain; Dermatitis, Phototoxic; Alpha-MSH; Dermatologic Agents. |
| Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications pmid:33683075 | 2021 | Review | other | Not stated | Indexed as review. study model from MeSH "Humans" with no interventional publication type. subject headings: Skin Diseases; Alpha-MSH; Dermatologic Agents; Skin Pigmentation; Age Factors. |
| Clinical and dermoscopic changes of acquired melanocytic nevi of patients treated with afamelanotide pmid:33721252 | 2021 | Journal Article | other | Not stated | Indexed as journal article. study model from MeSH "Humans" with no interventional publication type. subject headings: Nevus, Pigmented; Protoporphyria, Erythropoietic; Alpha-MSH; Receptor, Melanocortin, Type 1; Dermatologic Agents. |
Where this page sits
Compound page: Afamelanotide. Class: Melanocortin receptor peptides.
Retrieved 2026-10-10.
Sources
- PubChem Compound Summary for CID 16197727, Afamelanotide. PubChem, National Library of Medicine (2026). pubchem:16197727
- Drugs@FDA application register query for this compound, 1 application(s) returned: NDA210797. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:afamelanotide
- Afamelanotide for Erythropoietic Protoporphyria. N Engl J Med (2015). pmid:26132941
- Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria. Br J Dermatol (2015). pmid:25494545
- The efficacy of afamelanotide and narrowband UV-B phototherapy for repigmentation of vitiligo. JAMA Dermatol (2013). pmid:23407924
- Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. JAMA Dermatol (2015). pmid:25230094
- Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders. Clin Pharmacokinet (2017). pmid:28063031
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.